Information Provided By:
Fly News Breaks for July 6, 2015
VRTX
Jul 6, 2015 | 06:13 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Vertex Pharmaceuticals to $161 after the FDA approved Orkambi in homozygous F508del cystic fibrosis patients aged 12 and older. Tenthoff points out that while the drug's annual price of $259,000 missed his estimate, the number is still above the consensus estimate. He reiterates an Overweight rating on Vertex.
News For VRTX From the Last 2 Days
There are no results for your query VRTX